These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23660946)

  • 1. ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines.
    Khursheed M; Kolla JN; Kotapalli V; Gupta N; Gowrishankar S; Uppin SG; Sastry RA; Koganti S; Sundaram C; Pollack JR; Bashyam MD
    Br J Cancer; 2013 May; 108(10):2056-62. PubMed ID: 23660946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
    Shain AH; Giacomini CP; Matsukuma K; Karikari CA; Bashyam MD; Hidalgo M; Maitra A; Pollack JR
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):E252-9. PubMed ID: 22233809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma.
    Tsuda M; Fukuda A; Kawai M; Araki O; Seno H
    Cancer Sci; 2021 Feb; 112(2):490-497. PubMed ID: 33301642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.
    Xu S; Furukawa T; Kanai N; Sunamura M; Horii A
    J Hum Genet; 2005; 50(4):159-167. PubMed ID: 15824892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
    Zhao L; Cui Q; Lu Z; Chen J
    Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang C; Yu S; Jia C; Yan J; Lu Z; Chen J
    Technol Cancer Res Treat; 2018 Jan; 17():1533034618754475. PubMed ID: 29486633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
    Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
    Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
    Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.
    Banine F; Bartlett C; Gunawardena R; Muchardt C; Yaniv M; Knudsen ES; Weissman BE; Sherman LS
    Cancer Res; 2005 May; 65(9):3542-7. PubMed ID: 15867346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.
    Köbel M; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Stewart CJR; Lee CH
    Am J Surg Pathol; 2018 Jan; 42(1):76-83. PubMed ID: 28863077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic analyses identify molecular subtypes of pancreatic cancer.
    Bailey P; Chang DK; Nones K; Johns AL; Patch AM; Gingras MC; Miller DK; Christ AN; Bruxner TJ; Quinn MC; Nourse C; Murtaugh LC; Harliwong I; Idrisoglu S; Manning S; Nourbakhsh E; Wani S; Fink L; Holmes O; Chin V; Anderson MJ; Kazakoff S; Leonard C; Newell F; Waddell N; Wood S; Xu Q; Wilson PJ; Cloonan N; Kassahn KS; Taylor D; Quek K; Robertson A; Pantano L; Mincarelli L; Sanchez LN; Evers L; Wu J; Pinese M; Cowley MJ; Jones MD; Colvin EK; Nagrial AM; Humphrey ES; Chantrill LA; Mawson A; Humphris J; Chou A; Pajic M; Scarlett CJ; Pinho AV; Giry-Laterriere M; Rooman I; Samra JS; Kench JG; Lovell JA; Merrett ND; Toon CW; Epari K; Nguyen NQ; Barbour A; Zeps N; Moran-Jones K; Jamieson NB; Graham JS; Duthie F; Oien K; Hair J; Grützmann R; Maitra A; Iacobuzio-Donahue CA; Wolfgang CL; Morgan RA; Lawlor RT; Corbo V; Bassi C; Rusev B; Capelli P; Salvia R; Tortora G; Mukhopadhyay D; Petersen GM; ; Munzy DM; Fisher WE; Karim SA; Eshleman JR; Hruban RH; Pilarsky C; Morton JP; Sansom OJ; Scarpa A; Musgrove EA; Bailey UM; Hofmann O; Sutherland RL; Wheeler DA; Gill AJ; Gibbs RA; Pearson JV; Waddell N; Biankin AV; Grimmond SM
    Nature; 2016 Mar; 531(7592):47-52. PubMed ID: 26909576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SWI/SNF complex and cancer.
    Reisman D; Glaros S; Thompson EA
    Oncogene; 2009 Apr; 28(14):1653-68. PubMed ID: 19234488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas.
    Wang W; Friedland SC; Guo B; O'Dell MR; Alexander WB; Whitney-Miller CL; Agostini-Vulaj D; Huber AR; Myers JR; Ashton JM; Dunne RF; Steiner LA; Hezel AF
    Gut; 2019 Jul; 68(7):1245-1258. PubMed ID: 30228219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of SWI/SNF mutations, ubiquitous in human cancers.
    Shain AH; Pollack JR
    PLoS One; 2013; 8(1):e55119. PubMed ID: 23355908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
    Xia W; Bai H; Deng Y; Yang Y
    J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas.
    Dal Molin M; Hong SM; Hebbar S; Sharma R; Scrimieri F; de Wilde RF; Mayo SC; Goggins M; Wolfgang CL; Schulick RD; Lin MT; Eshleman JR; Hruban RH; Maitra A; Matthaei H
    Hum Pathol; 2012 Apr; 43(4):585-91. PubMed ID: 21940037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas.
    Tessier-Cloutier B; Schaeffer DF; Bacani J; Marginean CE; Kalloger S; Köbel M; Lee CH
    Histopathology; 2020 Jul; 77(1):46-54. PubMed ID: 32413172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma.
    Costello LC; Levy BA; Desouki MM; Zou J; Bagasra O; Johnson LA; Hanna N; Franklin RB
    Cancer Biol Ther; 2011 Aug; 12(4):297-303. PubMed ID: 21613827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.